医学
痛风
荟萃分析
随机对照试验
重症监护医学
内科学
药理学
作者
Aihua Wang,Weilong Shi,Shouxin Zhang,Huilin Tang,Xin Feng
标识
DOI:10.1016/j.clinthera.2024.04.013
摘要
Previous studies have shown that newer glucose-lowering drugs (GLDs), such as sodium-glucose transport protein 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase 4 (DPP-4) inhibitors, may decrease the risk of gout, however, the evidence remains inconclusive. This study aimed to assess the association between newer GLDs and risk of gout.
科研通智能强力驱动
Strongly Powered by AbleSci AI